Navigation Links
Neurocrine Announces Positive Results of VMAT2 Inhibitor NBI-98854 in Kinect 2 Study
Date:1/6/2014

final two weeks of treatment. The primary endpoint of the study was a comparison of placebo vs. active scores utilizing the AIMS at the end of Week 6 by blinded central raters.

About the Abnormal Involuntary Movement Scale (AIMS)The AIMS is a structured neurological examination that was developed in 1976 and has been used extensively in movement disorder assessments. It consists of ten distinct ratings of regional involuntary body movements that are scored on a zero to four scale with zero being rated as none and four being rated as severe. The primary endpoint of the Kinect 2 Study is the video AIMS total dyskinesia score, items one through seven which rate facial, extremity and trunk movement severity as assessed by blinded central raters. The raters were movement disorder neurologists with expertise in dyskinesia assessment.

About Tardive DyskinesiaTardive dyskinesia is characterized by involuntary, repetitive movements of the extremities: lip smacking, grimacing, tongue protrusion, facial movements or blinking, puckering and pursing of the lips, or involuntary movements of the limbs. These symptoms are rarely reversible and there is currently no approved treatment.

About NBI-98854VMAT2 is a protein concentrated in the human brain that is primarily responsible for re-packaging and transporting monoamines (dopamine, norepinephrine, serotonin, and histamine) in pre-synaptic neurons. NBI-98854, developed in the Neurocrine laboratories, is a novel, highly-selective VMAT2 inhibitor that modulates dopamine release during nerve communication, while at the same time having minimal impact on the other monoamines, thereby reducing the likelihood of "off target" side effects.  NBI-98854 is designed to provide low, sustained, plasma and brain concentrations of active drug to minimize side effects associated with excessive monoamine depletion. The Company has completed nine-month in-vivo toxicology studies to support longer dosing regimens in humans.
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neurocrine Biosciences To Present At Oppenheimers 24th Annual Healthcare Conference
2. Neurocrine Biosciences Announces Conference Call And Webcast To Present Third Quarter 2013 Financial Results
3. Clinical Trial Results, Litigation Outcomes and Marketing Authorizations - Research Report on Pfizer, GlaxoSmithKline, Sanofi, AstraZeneca, and Neurocrine
4. Neurocrine Announces Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia
5. Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
6. Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis
7. Neurocrine Biosciences to Present at the Jefferies 2013 Global Healthcare Conference
8. Neurocrine Biosciences to Present At The Deutsche Bank 38th Annual dbAccess Health Care Conference
9. Neurocrine Biosciences Reports First Quarter 2013 Results
10. Neurocrine Biosciences to Present at the Needham 12th Annual Healthcare Conference
11. Neurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... MADISON, N.J. , Oct. 22, 2014  Quest ... provider of diagnostic information services, today announced that its ... Ph.D., to serve as a director, effective December 1, 2014. ... Dr. Leiden is the Chairman, President and CEO ... 20 years of scientific and commercial experience in the ...
(Date:10/22/2014)... , Oct. 22, 2014  Charlene Vernak, RPh, of ... , recently was awarded the George Roentsch Scholarship ... received the award in Houston ... scholarship is awarded annually to an independent pharmacist and ... of George Roentsch , a well-known pharmacist in ...
(Date:10/22/2014)... 22, 2014  Paper Pak Industries, a manufacturer ... ® Body Guard Bio, a disposable, highly ... bacteria and virus while protecting service providers and ... features a rugged, external nylon shell, watertight zipper, ... leak-proof inner chamber that contains contaminated and potentially ...
Breaking Medicine Technology:Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 2Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 3PCCA Awards Charlene Vernak, RPh, the George Roentsch Scholarship 2New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2
... 27 For the first time ever, large numbers of personnel ... ChemOutsourcing at the Jersey Shore this fall. Most are chemists by training ... , , , ... found a home on the East Coast where the majority of the ...
... 27 BioElectronics Corp. (Pink Sheets: BIEL), manufacturers of ... for Japan , YesDTC Holdings, Inc. (OTC Bulletin Board: ... pending review by Japanese government medical device regulators for the ... place on Wednesday, July 28th . , ...
Cached Medicine Technology:Big Pharma Chemists Turning Out in Large Numbers for ChemOutsourcing Extravaganza Event on September 14-16, 2010 at Jersey Shore Beach Resort 2BioElectronics and YesDTC Holdings Receive Japanese Regulatory Review Date 2
(Date:10/25/2014)... Market Research Report on ... is a professional and in-depth market survey ... The report firstly reviews the basic information ... and manufacturing technology. The report then explores ... Diagnostics listing their product specification, capacity, Production ...
(Date:10/25/2014)... NC (PRWEB) October 25, 2014 Mesothelioma ... who continued to receive pemetrexed (Alimta), after his combination ... read the full story , just posted on the ... from Uji Tokushukai Medical Center in Japan suggests that ... mesothelioma patients who cannot tolerate higher doses ...
(Date:10/25/2014)... getting the right amount of sleep might raise your ... Those who sleep less or more than the recommended ... prone to developing the chronic condition, which causes inflammation ... that duration and quality of sleep are key factors ... "Both short and long durations of sleep have ...
(Date:10/25/2014)... Randy Dotinga HealthDay Reporter ... tests are developed that spot increased risks for certain cancers, ... about getting screened. But a new study suggests that, ... People who found out their genes doubled their risk of ... risk to get screened. "It didn,t make any difference, ...
(Date:10/22/2014)... On October 22, CBS will air an episode ... fictional and real. The Charles E Holman Morgellons ... advocacy and philanthropy in the battle against Morgellons Disease, ... impart truth and clarity about this misunderstood and routinely ... about Morgellons Disease (MD) and most people ...
Breaking Medicine News(10 mins):Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3
... an incidence rate between 0 and 2.6% (average 0.3%) in ... generally well tolerated by patients, causing a delay in medical ... pediatrician faced with diagnosis and treatment of tinea of the ... tinea of the nails was observed in the Hospital del ...
... wellbeing in rich countries might depend more on reductions in ... study published today on bmj.com . , Poorer ... But a recent UNICEF report detailing 40 indicators of ... fared worse than in any of the other rich countries. ...
... Treatment ... Worldwide, LOS ANGELES, Nov. ... develop an AIDS vaccine have,announced that their efforts have stumbled or, in ... was halted last week,when its vaccine was suspected of actually making some ...
... Patients Ages 10 to 17 ... ... ,Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE:,BMY) announced today that ... a Priority Review to the supplemental New,Drug Application (sNDA) of the atypical ...
... care fraud,becoming more organized, sophisticated, and prevalent, ... Investigative Units,(SIUs), state and federal agencies, and ... Health Care Anti-Fraud Association (NHCAA),s Annual,Training Conference, ... learn,more about new fraud schemes and explore ...
... against prescribing drug to patients who are already depressed ... take the weight-loss drug rimonabant may face heightened risks ... The finding follows a recommendation by a U.S. Food ... not approve the diet drug because of continuing concerns ...
Cached Medicine News:Health News:Tinea of the nails underdiagnosed in children 2Health News:Low standards of child well-being linked to greater income inequality 2Health News:AIDS Vaccine Failures Highlight Need to Focus on Lifesaving Treatment, Says AHF 2Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 2Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 3Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 4Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 5Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 6Health News:NHCAA Annual Training Conference Bringing Together Law Enforcement, Health Insurers to Fight Health Care Fraud 2Health News:NHCAA Annual Training Conference Bringing Together Law Enforcement, Health Insurers to Fight Health Care Fraud 3Health News:Diet Drug Rimonabant Tied to Depression, Anxiety 2Health News:Diet Drug Rimonabant Tied to Depression, Anxiety 3
Synchron CX3 Delta is a critical care clinical system, providing unparalleled testing speed for the most frequently ordered chemistries-Glucose, BUN, Creatinine, Sodium, Potassium Chloride, CO2 Calci...
Iron (Total/Ferene). Storage temp: 15 - 30 C. Linearity: 0 - 500 ug/dl. Expected values: from males 60 - 160 ug/dl, from females 43 - 140 ug/dl. Available with Calibrator and Number of test are 120....
For the quantitative determination of iron, total iron-binding capacity in human serum....
HDL Cholesterol, liquid....
Medicine Products: